Payment overview · 2025
General Payments
$871.62
31 reported records · 8 companies
Healthcare provider profile · identity verified
Anthony Amoako Addae
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MANSFIELD, TX · NPI 1962964791
Verified facts
What the public records show
CMS Open Payments records show Anthony Amoako Addae received $871.62 in general payments during 2025 across 31 reported records.
Astellas Pharma US Inc accounted for 38.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $336.81 | 38.6% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $211.56 | 24.3% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $105.66 | 12.1% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $78.23 | 9.0% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.04 | 6.4% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $41.23 | 4.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.85 | 3.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.24 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $612.58 | 28 |
| Education | $259.04 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $211.56 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $183.89 | 8 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $77.77 | 4 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $56.04 | 2 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $56.04 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $41.23 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 109 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
76 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
109 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 744 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 660 | 127 |
| Furosemide | Furosemide | 650 | 177 |
| Pantoprazole Sodium | Pantoprazole Sodium | 504 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 488 | 92 |
| Potassium Chloride | Potassium Chloride | 472 | 142 |
| Donepezil Hcl | Donepezil Hcl | 456 | 98 |
| Trazodone Hcl | Trazodone Hcl | 438 | 109 |
| Memantine Hcl | Memantine Hcl | 396 | 76 |
| Gabapentin | Gabapentin | 393 | 80 |
| Mirtazapine | Mirtazapine | 392 | 82 |
| Escitalopram Oxalate | Escitalopram Oxalate | 375 | 64 |
| Sertraline Hcl | Sertraline Hcl | 373 | 89 |
| Losartan Potassium | Losartan Potassium | 354 | 67 |
| Eliquis | Apixaban | 323 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 319 | 70 |
| Carvedilol | Carvedilol | 300 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 289 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 64 |
| Omeprazole | Omeprazole | 254 | 40 |
| Lisinopril | Lisinopril | 247 | 59 |
| Metformin Hcl | Metformin Hcl | 237 | 48 |
| Divalproex Sodium | Divalproex Sodium | 228 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 228 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 215 | 52 |
| Buspirone Hcl | Buspirone Hcl | 211 | 52 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 187 | 145 |
| Clopidogrel | Clopidogrel Bisulfate | 187 | 42 |
| Alprazolam | Alprazolam | 185 | 56 |
| Methylprednisolone | Methylprednisolone | 177 | 136 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 175 | 46 |
| Azithromycin | Azithromycin | 170 | 133 |
| Tramadol Hcl | Tramadol Hcl | 158 | 59 |
| Allopurinol | Allopurinol | 155 | 36 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 146 | 107 |
| Metolazone | Metolazone | 131 | 38 |
| Montelukast Sodium | Montelukast Sodium | 130 | 29 |
| Jardiance | Empagliflozin | 127 | 21 |
| Prednisone | Prednisone | 126 | 63 |
| Citalopram Hbr | Citalopram Hydrobromide | 124 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 25 |
| Latanoprost | Latanoprost | 111 | 25 |
| Gemtesa | Vibegron | 109 | 24 |
| Cephalexin | Cephalexin | 104 | 81 |
| Finasteride | Finasteride | 99 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 94 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 22 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 92 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 35 |
| Famotidine | Famotidine | 88 | 25 |
| Pregabalin | Pregabalin | 85 | 20 |
| Lorazepam | Lorazepam | 84 | 30 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 81 | 25 |
| Nystatin | Nystatin | 80 | 40 |
| Olanzapine | Olanzapine | 80 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 78 | 18 |
| Myrbetriq | Mirabegron | 76 | 15 |
| Levetiracetam | Levetiracetam | 74 | 12 |
| Bupropion Xl | Bupropion Hcl | 73 | 13 |
| Nifedipine Er | Nifedipine | 73 | 18 |
| Warfarin Sodium | Warfarin Sodium | 70 | suppressed |
| Simvastatin | Simvastatin | 69 | 16 |
| Lactulose | Lactulose | 68 | 41 |
| Risperidone | Risperidone | 68 | 16 |
| Sucralfate | Sucralfate | 68 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 64 |
| Ondansetron Hcl | Ondansetron Hcl | 67 | 50 |
| Bumetanide | Bumetanide | 64 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 15 |
| Xarelto | Rivaroxaban | 64 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 19 |
| Rivastigmine | Rivastigmine | 57 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 56 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 12 |
| Brimonidine Tartrate | Brimonidine Tartrate | 53 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 52 | 11 |
| Baclofen | Baclofen | 51 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 51 | 39 |
| Flecainide Acetate | Flecainide Acetate | 51 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 50 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 49 | suppressed |
| Cefdinir | Cefdinir | 48 | 46 |
| Fluconazole | Fluconazole | 48 | 25 |
| Loperamide | Loperamide Hcl | 48 | 35 |
| Atenolol | Atenolol | 47 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | suppressed |
| Ibuprofen | Ibuprofen | 46 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Mupirocin | Mupirocin | 46 | 36 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | suppressed |
| Glipizide | Glipizide | 45 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Methocarbamol | Methocarbamol | 41 | 16 |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 12 |
| Megestrol Acetate | Megestrol Acetate | 39 | 17 |
| Midodrine Hcl | Midodrine Hcl | 39 | 12 |
| Spironolactone | Spironolactone | 39 | 12 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 38 | 32 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Sulindac | Sulindac | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Meloxicam | Meloxicam | 36 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 35 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 34 | 34 |
| Temazepam | Temazepam | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 26 |
| Diltiazem 24hr Er | Diltiazem Hcl | 33 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 33 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 22 |
| Klor-Con 10 | Potassium Chloride | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 12 |
| Torsemide | Torsemide | 27 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 24 |
| Digoxin | Digoxin | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Folic Acid | Folic Acid | 25 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 24 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Nabumetone | Nabumetone | 22 | suppressed |
| Ramelteon | Ramelteon | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 19 | 16 |
| Nystop | Nystatin | 19 | 13 |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Trospium Chloride | Trospium Chloride | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Repaglinide | Repaglinide | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 15 | 11 |
| Haloperidol | Haloperidol | 15 | suppressed |
| Hydroxyurea | Hydroxyurea | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $871.62 · 31 records | Astellas Pharma US Inc | ACCRUFER, GEMTESA, MOUNJARO, NUZYRA, REXULTI, Veozah, XHANCE, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error